HC Wainwright Reaffirms Neutral Rating for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ:ATRA)‘s stock had its “neutral” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. HC Wainwright also issued estimates for Atara Biotherapeutics’ Q3 2025 earnings at $3.57 EPS.

ATRA has been the topic of several other reports. RODMAN&RENSHAW lowered Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 21st. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. Canaccord Genuity Group reduced their target price on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, January 17th. Finally, Rodman & Renshaw assumed coverage on shares of Atara Biotherapeutics in a research note on Friday, December 20th. They set a “buy” rating and a $25.00 price target on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Atara Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $17.75.

Atara Biotherapeutics Price Performance

NASDAQ ATRA opened at $8.09 on Tuesday. The firm has a market capitalization of $46.60 million, a price-to-earnings ratio of -0.31 and a beta of 0.51. The company has a 50 day simple moving average of $11.78 and a 200-day simple moving average of $9.93. Atara Biotherapeutics has a 52-week low of $5.40 and a 52-week high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter in the previous year, the company earned ($16.50) EPS. On average, analysts predict that Atara Biotherapeutics will post -9.86 EPS for the current year.

Hedge Funds Weigh In On Atara Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its holdings in shares of Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 4,043 shares in the last quarter. State Street Corp lifted its position in shares of Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after buying an additional 7,680 shares during the last quarter. FMR LLC lifted its position in shares of Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after buying an additional 7,381 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Atara Biotherapeutics in the second quarter valued at about $79,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Atara Biotherapeutics in the second quarter valued at about $53,000. 70.90% of the stock is owned by institutional investors and hedge funds.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.